MediVision Medical Imaging Ltd. ?+(972) 4-989-4884 ?+(972) 4-989-4883

? 26 Sweden St. Haifa, Israel 34980

? noam@medivision.co.il

FOR IMMEDIATE RELEASE REGULATED INFORMATION Changes to the Board Members and Remuneration

Haifa, Israel, December 13th, 2012 - MediVision Medical Imaging Ltd. (the "Company", EuroNext: MEDV)
reports hereby, that on November 27th 2012, its Board of Directors (the "Board") approved the following:
1. The nomination of a Compensation Committee, required under a recent amendment to the Israeli Companies Law, 5759-1999 (the "Israeli Companies Law"), which will revise the company's compensation procedures and policy in connection with remuneration of its officers and directors.
In light of their qualifications, the Board nominated Messrs. Doron Lifshitz, Orly Steinberg and Amnon Rofe as members of the Compensation Committee and designated Mr. Doron Lifshitz to be the chairman thereof.
2. Further to the Board's recent resolution recommending the Company's shareholders to approve the appointment of Mr. Gil Allon as a member of the Company's Board, the Board approved the appointment of Mr. Gil Allon to immediately serve as a member of the Board. Mr. Gil Allon is a controlling shareholder of the Company and the brother of Mr. Noam Allon, the Company's CEO.
3. Further to the foregoing, the Board also approved the inclusion of Mr. Gil Allon in the Company's D&O Liability insurance coverage upon the terms and conditions granted to other company's officers and controlling shareholders, with effect as of the beginning of his term of office.
4. Contemplating the short remainder of time to the validity of the Company's 2004 ESOP, the Board adopted a new employee share option plan, basically upon the same terms but for a longer period, and approved reserving five hundred thousand (500,000) Ordinary Shares of the Company, NIS 0.1 nominal value each, out of the Company's registered and un-issued share capital, for issuance upon exercise of options granted under such plan.
5. Subject to the approval of the Company's shareholders, required under the Israeli Companies Law, the Board approved the terms of office of the Company's CEO, Mr. Noam Allon, and its new CFO, Mr. Ariel Shenhar, in light of management's increased scope of its activities.
The compensation terms include: (i) 60% of a full time office, on the basis of a gross sum (for a full time officer) of NIS 50,000 for Mr. Allon and NIS 45,000 for Mr. Shenhar, with additional percentage rate fees to be added in respect of their actual services provided to the Company and additional sums to each, representing the fees being services fees rather than salaries; (i) a compensation of travel expenses and certain other expenses; and (ii) granting of immediately vested options exercisable during a 10 year period into 500,000 Company shares (400,000 to Mr. Allon and 100,000 to Mr. Shenhar), at an exercise price equal to the average price of the Company's shares on the stock exchange during the 30 day period immediately prior to the approval.
The foregoing is subject to further discussions at and approvals of the Company's special general meeting of the shareholders, to be convened by management together with additional details and all relevant information as to the subject matters hereof.

This Report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of the Management of the Company as well as assumptions made by and information currently available to the Management of the Company. Such statements reflect the current views of th e Company with respect to future events, the outcome of which is subject to certain risks including but not limited to as listed below and other factors, which may be outside of the Company's control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results of outcomes may vary materially from those described herein as projected, anticipated, believed, estimated, expected or intended. Such abovementioned risks include but are not limited to:

1. Uncertain market acceptance of Company products - The Company's future growth and profitability will depend, in large part, on the acceptance by the market of the Company's existing

and proposed products. This acceptance will be substantially dependent on educating the market as to full capabilities, disti nctive characteristics, perceived benefits and efficacy of the Company's existing and proposed products. In addition, the future success of the Company's products will depend on their acce ptance by customers and on such customers' willingness and ability to purchase such products. There can be no assurance that the Company's products will receive the necessary market acceptance. Fail ure of the Company's existing and/or proposed products to gain market acceptance could have a material adverse effect on the Company's business, financial condition and results of operations.

2. New products - The Company, through its Research and Development teams, engages in the development of new technologies and products and in the upgrading and improvement of

existing ones. There is no certainty that development of these technologies and/or products will be completed, successfully, or at all, or if comp leted successfully, that a market for them will exist.

distributed by